Volume 82, Issue 2, Pages (July 2012)

Slides:



Advertisements
Similar presentations
Pathologic Diagnosis in Amyloidosis
Advertisements

M protein detection and characterization
Melamine toxicity: one more culprit in calcium kidney lithiasis
Propofol-related green urine
Graft pyelonephritis causing graft failure from de novo AA amyloid
Volume 75, Issue 9, Pages (May 2009)
Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the.
by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi
Shining light on vitamin D trials in chronic kidney disease
A Patient With Hereditary ATTR and a Novel AGel p
Renal Manifestations of Plasma Cell Disorders
Recurrent AA Amyloidosis in a Kidney Transplant
Christophe Sirac, Frank Bridoux  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
C-reactive protein and dialysis access
Volume 76, Issue 4, Pages (August 2009)
Volume 77, Issue 1, Pages 6-8 (January 2010)
Volume 81, Issue 4, Pages (February 2012)
Volume 77, Issue 9, Pages (May 2010)
Volume 58, Issue 1, Pages (July 2000)
Quiz Page July 2007 American Journal of Kidney Diseases
Better nephrology for mice—and man
AJKD Atlas of Renal Pathology: Hereditary and Other Non-AL Amyloidoses
Volume 73, Issue 11, Pages (June 2008)
Volume 77, Issue 9, Pages (May 2010)
Medullary amyloidosis associated with apolipoprotein A-IV deposition
Methotrexate in the urine
Comorbidity and confounding in end-stage renal disease
Punit Yadav, Nelson Leung, Paul W. Sanders, Paul Cockwell 
Emerging treatments for amyloidosis
Volume 70, Issue 11, Pages (December 2006)
New Clinical Insights Into the Pathology of Amyloidosis
Volume 86, Issue 2, Pages (August 2014)
Alect2 amyloidosis: primum non nocere (first, do no harm)
Volume 87, Issue 2, Pages (February 2015)
Volume 88, Issue 4, Pages (October 2015)
Myeloma cast nephropathy, direct renal infiltration by myeloma, and renal extramedullary hematopoiesis  S.H. Nasr, B.B. Alobeid, J.A. Otrakji, G.S. Markowitz 
Volume 71, Issue 6, Pages (March 2007)
Volume 85, Issue 2, Pages (January 2014)
Volume 85, Issue 6, Pages (June 2014)
Melamine toxicity: one more culprit in calcium kidney lithiasis
Volume 76, Issue 5, Pages (September 2009)
Response to ‘Hepcidin levels in patients with renal disease’
Volume 82, Issue 1, Pages 3-4 (July 2012)
Disaster nephrology: crush injury and beyond
A physician's perseverance uncovers problems in a key nephrology study
Dental caries in renal tubular acidosis
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Myeloproliferative neoplasms cause glomerulopathy
Thomas Mueller, Benjamin Dieplinger  Kidney International 
Immunofluorescence on pronase-digested paraffin sections: A valuable salvage technique for renal biopsies  S.H. Nasr, S.J. Galgano, G.S. Markowitz, M.B.
Volume 67, Issue 1, Pages (January 2005)
Nephrology Crossword: Glomerulonephritis
Masahide Yazaki, Sandra A. Farrell, Merrill D. Benson 
Volume 82, Issue 4, Pages (August 2012)
Volume 73, Issue 9, Pages (May 2008)
The Case ∣ Hypocalcemia, chronic renal failure and dysmorphism?
Volume 59, Issue 5, Pages (May 2001)
Volume 80, Issue 10, Pages (November 2011)
Localized bladder amyloidosis mimicking bladder carcinoma
Volume 64, Issue 1, Pages (July 2003)
Leukocyte chemotactic factor 2: A novel renal amyloid protein
The more or less ‘pristine’ renal allograft biopsy
Volume 68, Issue 5, Pages (November 2005)
T cells and T-cell receptors in acute renal failure
Volume 85, Issue 4, Pages (April 2014)
The Ebf1 knockout mouse and glomerular maturation
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Tissue proteomics: a new investigative tool for renal biopsy analysis
Presentation transcript:

Volume 82, Issue 2, Pages 226-234 (July 2012) Laser microdissection and mass spectrometry–based proteomics aids the diagnosis and typing of renal amyloidosis  Sanjeev Sethi, Julie A. Vrana, Jason D. Theis, Nelson Leung, Anjali Sethi, Samih H. Nasr, Fernando C. Fervenza, Lynn D. Cornell, Mary E. Fidler, Ahmet Dogan  Kidney International  Volume 82, Issue 2, Pages 226-234 (July 2012) DOI: 10.1038/ki.2012.108 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 Laser microdissection. Congo red–positive (a) glomeruli, (b) vessels, and (c) interstitium marked for microdissection. (d) Empty space following microdissection of glomeruli from a. Kidney International 2012 82, 226-234DOI: (10.1038/ki.2012.108) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 2 Mass spectrometry by spectra. (a) Representative mass spectrometry data by spectral analyses from a case of AL lambda light-chain amyloidosis (AL-lambda), AL kappa light-chain amyloidosis (AL-kappa), heavy-chain amyloidosis (AH), AA amyloidosis (AA), fibrinogen-α amyloidosis (AFib), LECT-2 amyloidosis (ALect2), transthyretin (TTR) amyloidosis (ATTR), gelsolin amyloidosis (AGel), and apolipoprotein A-IV amyloidosis (ApoAIV). The probability number (>95% is highlighted in green, 80–94% in yellow) indicates essentially the percent homology between peptides detected in the specimens and the published amino-acid sequences of their corresponding proteins. VOR, NEWM, and Rei are names that have been given to specific sequences of variable regions. (b) Representative mass spectrometry data from a case of fibrinogen-α amyloidosis showing both the fibrinogen-α chain and the mutated fibrinogen-α peptide. (c) Representative mass spectrometry data from day 0 protocol allograft biopsies in seven cases. Red star indicates shared peptides between different proteins. Ig, immunoglobulin. Kidney International 2012 82, 226-234DOI: (10.1038/ki.2012.108) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 Percentage sequence (peptide) coverage. Representative sequence (peptide) coverage of the protein detected in the microdissected sample showing: (a) 15 total spectra, 6 unique spectra, and 5 unique peptides for 64% coverage of Ig lambda light-chain constant region with 100% probability; (b) 8 total spectra, 2 unique spectra, and 2 unique peptides for 15% coverage of Ig lambda light chain variable I region with 100% probability; (c) 18 total spectra, 6 unique spectra, and 4 unique peptides for 64% coverage of Ig kappa light-chain constant region with 100% probability; (d) 4 total spectra, 2 unique spectra, and 2 unique peptides for 19% coverage of IgG1 heavy constant chain with 100% probability; (e) 5 total spectra, 3 unique spectra, and 3 unique peptides for 8% coverage of IgG3 heavy constant chain with 100% probability; (f) 37 total spectra, 7 unique spectra, and 6 unique peptides for 35% coverage of serum amyloid A (SAA) protein with 100% probability; (g) 42 total spectra, 11 unique spectra, and 10 unique peptides for 10% coverage of fibrinogen-α protein with 100% probability; (h) 11 total spectra, 4 unique spectra, and 4 unique peptides for 23% coverage of LECT2 with 100% probability; (i) 33 total spectra, 16 unique spectra, and 16 unique peptides for 17% coverage of gelsolin protein with 100% probability; (j) 11 total spectra, 7 unique spectra, and 5 unique peptides for 32% coverage of β-2 microglobulin with 100% probability; and (k) 37 total spectra, 16 unique spectra, and 14 unique peptides for 63% coverage of transthyretin (TTR) with 100% probability. The yellow highlighted areas show the actual peptides detected by the mass spectrometry, and the green highlighted areas show oxidized or methylated amino acids. Kidney International 2012 82, 226-234DOI: (10.1038/ki.2012.108) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 Percentage sequence (peptide) coverage. Representative sequence (peptide) coverage of the protein detected in the microdissected sample showing: (a) 15 total spectra, 6 unique spectra, and 5 unique peptides for 64% coverage of Ig lambda light-chain constant region with 100% probability; (b) 8 total spectra, 2 unique spectra, and 2 unique peptides for 15% coverage of Ig lambda light chain variable I region with 100% probability; (c) 18 total spectra, 6 unique spectra, and 4 unique peptides for 64% coverage of Ig kappa light-chain constant region with 100% probability; (d) 4 total spectra, 2 unique spectra, and 2 unique peptides for 19% coverage of IgG1 heavy constant chain with 100% probability; (e) 5 total spectra, 3 unique spectra, and 3 unique peptides for 8% coverage of IgG3 heavy constant chain with 100% probability; (f) 37 total spectra, 7 unique spectra, and 6 unique peptides for 35% coverage of serum amyloid A (SAA) protein with 100% probability; (g) 42 total spectra, 11 unique spectra, and 10 unique peptides for 10% coverage of fibrinogen-α protein with 100% probability; (h) 11 total spectra, 4 unique spectra, and 4 unique peptides for 23% coverage of LECT2 with 100% probability; (i) 33 total spectra, 16 unique spectra, and 16 unique peptides for 17% coverage of gelsolin protein with 100% probability; (j) 11 total spectra, 7 unique spectra, and 5 unique peptides for 32% coverage of β-2 microglobulin with 100% probability; and (k) 37 total spectra, 16 unique spectra, and 14 unique peptides for 63% coverage of transthyretin (TTR) with 100% probability. The yellow highlighted areas show the actual peptides detected by the mass spectrometry, and the green highlighted areas show oxidized or methylated amino acids. Kidney International 2012 82, 226-234DOI: (10.1038/ki.2012.108) Copyright © 2012 International Society of Nephrology Terms and Conditions